Skip to main content
. 2023 Jun 8;10(4):2524–2533. doi: 10.1002/ehf2.14426

Table 3.

The results from base‐case analysis

Total cost ($) Total life years (QALY) Incremental cost ($) Incremental life years (QALY) ICER ($ per QALY)
Dapagliflozin group 7245.77 6.00 1838.22 0.15 11 865.33
Control group 5407.55 5.84

QALY, quality‐adjusted life‐year.